News
Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide
In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and enzalutamide, reports the latest analysis of the CARD trial (Fizazi K et al. Lancet Oncol 2020). “This analysis can provide reassurance to physicians and patients […]